Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Non Small Cell Lung Cancer
PFS, Progression free survival, may 2020- may 2021 (1 year)
OS, Overall survival, may 2020- may 2021 (1 year)|ORR, To measure the patients's overall response rate, may 2020- may 2021 (1 year)
Inclusion criteria:

diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT